Nifty
:
25496.55
Sensex
:
82248.61
14.05 (0.06%)
-27.46 (-0.03%)
Nifty
Sensex
:
:
25496.55
82248.61
14.05 (0.06%)
-27.46 (-0.03%)

Piramal Pharma Ltd.

Pharmaceuticals & Drugs

Rating :
52/99

BSE: 543635 | NSE: PPLPHARMA

NSE BSE
162.42
26-Feb-2026
  • Open
  • High
  • Low
  • Previous Close
  •  161.19
  •  164.59
  •  159.8
  •  161.06
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3340011
  •  539602393.73
  •  240.95
  •  148.31

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 21,553.76
  • N/A
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 25,747.62
  • 0.09%
  • 2.70

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 34.86%
  • 1.30%
  • 14.11%
  • FII
  • DII
  • Others
  • 29.66%
  • 15.41%
  • 4.66%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 7.70
  • 8.92

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -0.14
  • 17.68

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -35.79
  • 115.07

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 2.77

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 19.65

Earnings Forecasts:

(Updated: 21-02-2026)
Description
2024
2025
2026
2027
Adj EPS
0.69
-0.46
2.41
5.13
P/E Ratio
233.42
-350.13
66.83
31.40
Revenue
9061
8947.11
10338.8
11894.1
EBITDA
1444.83
968.5
1551.82
2063.95
Net Income
91.13
-87.81
303.56
666.15
ROA
0.59
0.5
3.07
5.5
P/B Ratio
2.63
2.62
2.48
2.35
ROE
1.14
-0.9
3.94
7.65
FCFF
-164.17
552.76
183.78
500.82
FCFF Yield
-0.64
2.15
0.71
1.95
Net Debt
3824.57
3985.25
4148.5
3885.48
BVPS
61.29
61.5
64.84
68.46

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
2,139.87
2,204.22
-2.92%
2,043.72
2,241.75
-8.83%
1,933.71
1,951.14
-0.89%
2,754.07
2,552.36
7.90%
Expenses
1,944.14
1,866.48
4.16%
1,885.03
1,900.14
-0.80%
1,827.01
1,746.65
4.60%
2,193.08
2,022.43
8.44%
EBITDA
195.73
337.74
-42.05%
158.69
341.61
-53.55%
106.70
204.49
-47.82%
560.99
529.93
5.86%
EBIDTM
9.15%
15.32%
7.76%
15.24%
5.52%
10.48%
20.37%
20.76%
Other Income
43.24
12.13
256.47%
65.60
61.11
7.35%
58.40
19.54
198.87%
42.03
26.38
59.33%
Interest
89.24
103.31
-13.62%
82.42
107.64
-23.43%
86.15
106.96
-19.46%
103.68
114.22
-9.23%
Depreciation
212.74
196.81
8.09%
202.84
192.22
5.52%
197.28
184.55
6.90%
242.76
196.13
23.78%
PBT
-104.12
49.75
-
-60.97
102.86
-
-97.59
-67.48
-
256.58
215.44
19.10%
Tax
42.33
63.12
-32.94%
53.04
97.53
-45.62%
2.68
43.56
-93.85%
119.30
126.21
-5.48%
PAT
-146.45
-13.37
-
-114.01
5.33
-
-100.27
-111.04
-
137.28
89.23
53.85%
PATM
-6.84%
-0.61%
-5.58%
0.24%
-5.19%
-5.69%
4.98%
3.50%
EPS
-1.03
0.03
-
-0.75
0.17
-
-0.62
-0.67
-
1.16
0.77
50.65%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Net Sales
8,871.37
9,151.18
8,171.16
7,081.55
6,559.10
6,314.90
Net Sales Growth
-0.87%
11.99%
15.39%
7.97%
3.87%
 
Cost Of Goods Sold
3,137.84
3,231.65
2,954.00
2,703.30
2,451.26
2,059.11
Gross Profit
5,733.53
5,919.53
5,217.16
4,378.25
4,107.84
4,255.79
GP Margin
64.63%
64.69%
63.85%
61.83%
62.63%
67.39%
Total Expenditure
7,849.26
7,733.31
7,000.65
6,453.31
5,609.44
4,886.94
Power & Fuel Cost
-
267.16
241.59
207.81
163.56
136.70
% Of Sales
-
2.92%
2.96%
2.93%
2.49%
2.16%
Employee Cost
-
2,307.47
2,029.50
1,896.35
1,588.83
1,467.74
% Of Sales
-
25.21%
24.84%
26.78%
24.22%
23.24%
Manufacturing Exp.
-
774.18
731.64
674.10
589.03
544.09
% Of Sales
-
8.46%
8.95%
9.52%
8.98%
8.62%
General & Admin Exp.
-
563.04
542.00
472.78
428.49
367.25
% Of Sales
-
6.15%
6.63%
6.68%
6.53%
5.82%
Selling & Distn. Exp.
-
398.11
359.75
372.59
317.81
250.16
% Of Sales
-
4.35%
4.40%
5.26%
4.85%
3.96%
Miscellaneous Exp.
-
191.70
142.17
126.38
70.46
61.89
% Of Sales
-
2.09%
1.74%
1.78%
1.07%
0.98%
EBITDA
1,022.11
1,417.87
1,170.51
628.24
949.66
1,427.96
EBITDA Margin
11.52%
15.49%
14.32%
8.87%
14.48%
22.61%
Other Income
209.27
161.77
201.14
225.11
275.80
164.11
Interest
361.49
421.59
448.49
344.18
198.25
163.45
Depreciation
855.62
816.34
740.57
676.69
586.18
545.04
PBT
-6.10
341.71
182.59
-167.52
441.03
883.58
Tax
217.35
323.51
161.47
66.31
109.02
114.02
Tax Rate
-3,563.11%
94.67%
134.78%
-38.00%
25.59%
12.64%
PAT
-223.45
91.13
17.82
-186.46
375.96
835.03
PAT before Minority Interest
-223.45
91.13
17.82
-186.46
375.96
835.03
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-2.52%
1.00%
0.22%
-2.63%
5.73%
13.22%
PAT Growth
0.00%
411.39%
-
-
-54.98%
 
EPS
-1.68
0.69
0.13
-1.40
2.83
6.28

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Shareholder's Funds
8,125.47
7,911.37
6,773.50
6,696.60
5,605.00
Share Capital
1,324.35
1,322.95
1,193.32
1,185.91
994.60
Total Reserves
6,738.96
6,560.95
5,580.18
5,510.69
4,610.30
Non-Current Liabilities
3,392.72
2,644.64
3,812.00
2,902.58
2,560.38
Secured Loans
3,214.07
2,483.75
3,383.54
2,622.14
2,339.16
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
48.66
32.32
275.97
145.34
6.78
Current Liabilities
3,766.27
4,369.30
3,851.04
3,118.01
2,590.70
Trade Payables
1,533.77
1,538.37
1,192.71
1,026.35
917.94
Other Current Liabilities
1,184.72
1,575.68
1,305.30
1,242.76
1,140.63
Short Term Borrowings
995.32
1,171.38
1,302.29
658.76
360.52
Short Term Provisions
52.46
83.87
50.74
190.14
171.61
Total Liabilities
15,284.46
14,925.31
14,436.54
12,717.19
10,756.08
Net Block
8,133.43
7,989.93
7,468.60
6,879.18
6,105.49
Gross Block
13,117.63
12,137.48
10,842.12
9,510.49
8,173.25
Accumulated Depreciation
4,984.20
4,147.55
3,373.52
2,631.31
2,067.76
Non Current Assets
9,487.47
9,460.84
9,593.07
8,565.30
7,006.96
Capital Work in Progress
976.90
1,115.80
1,418.58
1,172.34
626.65
Non Current Investment
271.09
240.26
211.87
216.77
122.67
Long Term Loans & Adv.
91.08
114.85
493.98
296.97
152.11
Other Non Current Assets
14.97
0.00
0.04
0.04
0.04
Current Assets
5,796.99
5,464.47
4,843.47
4,151.89
3,749.12
Current Investments
19.56
144.69
427.11
50.40
0.00
Inventories
2,312.70
2,175.88
1,681.37
1,388.80
1,232.00
Sundry Debtors
2,349.52
2,134.43
1,799.34
1,785.28
1,574.94
Cash & Bank
501.46
482.56
307.56
328.99
405.62
Other Current Assets
613.75
81.93
140.24
93.66
536.56
Short Term Loans & Adv.
478.88
444.98
487.85
504.76
395.55
Net Current Assets
2,030.72
1,095.17
992.43
1,033.88
1,158.42
Total Assets
15,284.46
14,925.31
14,436.54
12,717.19
10,756.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Cash From Operating Activity
892.30
1,004.54
483.89
766.42
597.58
PBT
341.71
119.80
-160.56
441.03
639.68
Adjustment
1,372.66
1,275.88
1,135.53
787.10
721.99
Changes in Working Capital
-487.72
-234.30
-302.08
-292.29
-619.58
Cash after chg. in Working capital
1,226.65
1,161.38
672.89
935.84
742.09
Interest Paid
0.00
0.00
0.00
0.00
0.00
Tax Paid
-334.35
-156.84
-189.00
-169.42
-144.51
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-477.46
-434.01
-1,338.78
-1,812.10
-4,479.93
Net Fixed Assets
-285.13
-319.07
-350.70
-1,249.33
Net Investments
-1,397.15
38.83
-117.46
-38.01
Others
1,204.82
-153.77
-870.62
-524.76
Cash from Financing Activity
-440.83
-422.36
817.79
794.19
3,976.83
Net Cash Inflow / Outflow
-25.99
148.17
-37.10
-251.49
94.48
Opening Cash & Equivalents
219.19
53.23
85.18
261.97
151.95
Closing Cash & Equivalent
182.32
219.19
53.23
85.18
261.97

Financial Ratios

Standalone /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Book Value (Rs.)
60.88
59.59
55.44
55.15
56.35
ROA
0.60%
0.12%
-1.37%
3.20%
7.76%
ROE
1.14%
0.24%
-2.77%
6.11%
14.90%
ROCE
6.61%
5.07%
1.95%
7.10%
13.06%
Fixed Asset Turnover
0.84
0.82
0.80
0.83
0.77
Receivable days
77.05
76.20
80.70
83.94
91.03
Inventory Days
77.13
74.72
69.11
65.47
71.21
Payable days
173.49
168.73
149.81
144.76
162.72
Cash Conversion Cycle
-19.30
-17.80
0.00
4.65
-0.47
Total Debt/Equity
0.59
0.58
0.81
0.60
0.52
Interest Cover
1.98
1.40
0.65
3.45
6.81

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022

News Update:


  • USFDA concludes GMP inspection at Piramal Pharma’s Telangana facility
    16th Feb 2026, 09:49 AM

    At the conclusion of the inspection, the US FDA issued a Form-483, with 4 observations

    Read More
  • Piramal Pharma’s arm, Blue-Zone collaborate to recycle waste anaesthetic gases
    6th Feb 2026, 10:58 AM

    PCC will process captured waste anaesthetic gas using BlueZone’s technology to produce Sevoflurane USP for human use in Canada

    Read More
  • Piramal Pharma - Quarterly Results
    30th Jan 2026, 00:00 AM

    Read More
  • Piramal Pharma reports consolidated net loss of Rs 136.19 crore in Q3
    29th Jan 2026, 14:50 PM

    Total consolidated income of the company decreased by 1.50% at Rs 2,183.11 crore for Q3FY26

    Read More
  • Piramal Pharma’s arm inks pacts to acquire ‘Kenalog’ from BMS
    29th Jan 2026, 09:58 AM

    The said acquisition is expected to further leverage the company’s extensive distribution network spanning across 6,000 plus hospitals in more than 100 countries

    Read More
  • USFDA concludes GMP inspection at Piramal Pharma’s USA facility
    12th Dec 2025, 10:13 AM

    At the conclusion of the inspection, the USFDA issued a Form-483, with four observations

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.